Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00571194 · ClinicalTrials.gov registry record · Phase 1
Single Dose Pravastatin Pharmacokinetics in Pediatric Peritoneal Dialysis Patients
A Phase 1 study, sponsored by Arkansas Children's Hospital Research Institute.
- Terminated
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
NCT00571194 is a Phase 1 study that was terminated before completion, run by Arkansas Children's Hospital Research Institute. The registered enrollment target is 7 participants.
The verdict
NCT00571194, a Phase 1 study, was terminated before completion, sponsored by Arkansas Children's Hospital Research Institute.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
Many children with end stage renal disease develop hyperlipidemia. HMG-CoA (3-hydroxy-3-methylglutaryl-coenzyme A) reductase inhibitors, such as pravastatin, are typical treatments for hyperlipidemia. However, we do not know how pravastatin is metabolized in patients on dialysis. This study is designed to provide preliminary pharmacokinetic data for pravastatin in pediatric patients on peritoneal dialysis.
Interventions
- DRUG pravastatin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2007-09 |
| Est. Completion | 2009-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00571194
The ClinicalTrials.gov registry entry for NCT00571194 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Arkansas Children's Hospital Research Institute, which has 97 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which pravastatin is the first listed.
NCT00571194 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00571194 about?
NCT00571194 is a clinical study titled "Single Dose Pravastatin Pharmacokinetics in Pediatric Peritoneal Dialysis Patients". Many children with end stage renal disease develop hyperlipidemia. HMG-CoA (3-hydroxy-3-methylglutaryl-coenzyme A) reductase inhibitors, such as pravastatin, are typical treatments for hyperlipidemia. However, we do not know how pravastatin is metabolized in patients on dialysis. This study is desig...
What is the current status of trial NCT00571194?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2007-09. Estimated completion is 2009-05.
What interventions are being tested in trial NCT00571194?
The interventions under investigation include: pravastatin (DRUG).
Who is sponsoring clinical trial NCT00571194?
This trial is sponsored by Arkansas Children's Hospital Research Institute, which has 97 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.